In 2026, among defensive stocks, Johnson & Johnson outperformed with a 35% gain driven by strong oncology and immunology sales and a robust pipeline. Coca-Cola followed with a 28% rise, benefiting from steady global volume and pricing power, while Procter & Gamble lagged at 4% due to cost pressures and flat sales. This divergence highlights that defensive stocks' risk profiles don't always align with returns. Investors may favor JNJ and KO for their growth and stability, while waiting for PG to overcome its challenges.
Johnson & Johnson will report its Q3 2026 earnings on October 13, with analysts expecting earnings per share (EPS) of $2.66, a 5% decline from last year, while revenue is forecasted to grow 5.8% to $25.40 billion. Despite the EPS drop, the company ha...
Four Dividend Kings—Johnson & Johnson, Procter & Gamble, Coca-Cola, and PepsiCo—continue to deliver steady dividends, crucial for retirees relying on portfolio income. Johnson & Johnson and Procter & Gamble show very safe dividend payouts with health...
Johnson & Johnson announced two-year Phase 3 results for ICOTYDE (icotrokinra), an oral peptide targeting IL-23 receptor 1, showing sustained high skin clearance rates in adults and adolescents with moderate-to-severe plaque psoriasis. Nearly 72% of ...
Five major U.S. companies—Coca-Cola, Procter & Gamble, Johnson & Johnson, PepsiCo, and Realty Income—are highlighted for their long histories of dividend increases and strong cash flow coverage. These firms offer diverse dividend yields, with some pr...
Pfizer offers a dividend yield of 6.24%, much higher than Johnson & Johnson's 2.07%, but Pfizer's payout is frozen and not fully covered by free cash flow, with rising debt and a recent $4.3 billion write-down signaling risk. Johnson & Johnson, despi...
